Celgene receives positive CHMP opinion for OTEZLA® (apremilast)

Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation, announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for OTEZLA® (apremilast), the company’s oral selective inhibitor of phosphodiesterase 4 (PDE4), in two therapeutic indications.
Source: Pharmacy Europe - Category: Drugs & Pharmacology Authors: Tags: *** Editor's Pick Clinical trials Practical therapeutics Industry News Rheumatology apremilast chmp DMARDs Latest News OTEZLA PASI-75 PDE4 inhibitor psoriasis Source Type: news